In Vitro-In Vivo Correlation in Dermal Delivery: The Role of Excipients

被引:24
|
作者
Patel, Avnish [1 ]
Iliopoulos, Fotis [1 ]
Caspers, Peter J. [2 ,3 ]
Puppels, Gerwin J. [2 ,3 ]
Lane, Majella E. [1 ]
机构
[1] UCL Sch Pharm, Dept Pharmaceut, 29-39 Brunswick Sq, London WC1N 1AX, England
[2] RiverD Int BV, Marconistraat 16, NL-3029 AK Rotterdam, Netherlands
[3] Univ Med Ctr, Dept Dermatol, Ctr Optic Diagnost & Therapy, Erasmus MC, NL-3015 CN Rotterdam, Netherlands
基金
英国工程与自然科学研究理事会;
关键词
ibuprofen; excipients; skin delivery; Confocal Raman Spectroscopy; in vitro– in vivo correlation; TOPICAL DRUG-DELIVERY; PERCUTANEOUS-ABSORPTION; PROPYLENE-GLYCOL; SAFETY ASSESSMENT; CUTANEOUS PERMEATION; MODEL MEMBRANES; HUMAN SKIN; PENETRATION; IBUPROFEN; ENHANCEMENT;
D O I
10.3390/pharmaceutics13040542
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The composition of topical and transdermal formulations is known to determine the rate and the extent of drug delivery to and through the skin. However, to date, the role of excipients in these formulations on skin delivery of actives has received little attention from scientists in the field. Monitoring skin absorption of both drug and vehicle may provide insights into the mechanism by which excipients promote permeation and may facilitate the design of effective and safer products. Previously, we have investigated the use of quantitative Confocal Raman Spectroscopy (CRS) to investigate the delivery of an active to the skin, and we also reported the first fully quantitative study that compared this method with the well-established in vitro permeation test (IVPT) model. To further explore the potential of quantitative CRS in assessing topical delivery, the present work investigated the effects of commonly used excipients on the percutaneous absorption of a model drug, ibuprofen (IBU). Permeation of IBU and selected solvents following finite dose applications to human skin was determined in vitro and in vivo by Franz diffusion studies and quantitative CRS, respectively. The solvents used were propylene glycol (PG), dipropylene glycol (DPG), tripropylene glycol (TPG), and polyethylene glycol 300 (PEG 300). Overall, the cumulative amounts of IBU that permeated at 24 h in vitro were similar for PG, DPG, and TPG (p > 0.05). These three vehicles outperformed PEG 300 (p < 0.05) in terms of drug delivery. Concerning the vehicles, the rank order for in vitro skin permeation was DPG >= PG > TPG, while PEG 300 did not permeate the skin. A linear relationship between maximum vehicle and IBU flux in vitro was found, with a correlation coefficient (R-2) of 0.95. When comparing in vitro with in vivo data, a positive in vitro-in vivo (IVIV) correlation between the cumulative permeation of IBU in vitro and the total amount of IBU that penetrated the stratum corneum (SC) in vivo was observed, with a Pearson correlation coefficient (R-2) of 0.90. A strong IVIV correlation, R-2 = 0.82, was found following the linear regression of the cumulative number of solvents permeated in vitro and the corresponding skin uptake in vivo measured with CRS. This is the first study to correlate in vivo permeation of solvents measured by CRS with data obtained by in vitro diffusion studies. The IVIV correlations suggest that CRS is a powerful tool for profiling drug and vehicle delivery from dermal formulations. Future studies will examine additional excipients with varying physicochemical properties. Ultimately, these findings are expected to lead to new approaches for the design, evaluation, and optimization of formulations that target actives to and through the skin.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] In vitro-in vivo correlation of hepatobiliary drug clearance in humans
    Ghibellini, G.
    Vasist, L. S.
    Leslie, E. M.
    Heizer, W. D.
    Kowalsky, R. J.
    Calvo, B. F.
    Brouwer, K. L. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (03) : 406 - 413
  • [32] In Vitro-In Vivo Translation of Lipid Nanoparticles for Hepatocellular siRNA Delivery
    Whitehead, Kathryn A.
    Matthews, Jonathan
    Chang, Philip H.
    Niroui, Farnaz
    Dorkin, J. Robert
    Severgnini, Mariano
    Anderson, Daniel G.
    ACS NANO, 2012, 6 (08) : 6922 - 6929
  • [33] Lisinopril Oro-Dispersible Film: In Vitro-In Vivo Correlation
    Akhlaq, Muhammad
    Mudassir, Abdul M.
    Abdullah
    Nawaz, Asif
    Ullah, Hashmat
    Shahzad, Muhammad F.
    Imran, Muhammad
    Ramzan, Muhammad
    Ajaz, Mahvish
    Safdar, Muhammad
    Hussain, Abid
    LATIN AMERICAN JOURNAL OF PHARMACY, 2020, 39 (07): : 1379 - 1387
  • [34] Dependence of in vitro-in vivo correlation analysis acceptability on model selections
    Polli, JE
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 1999, 4 (01) : 89 - 96
  • [35] In Vitro-In Vivo Correlation of Modified Release Dosage Form of Lamotrigine
    Shah, Hiten J.
    Subbaiah, Gunta
    Patel, Dasharath M.
    Patel, Chhagan N.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2009, 30 (09) : 524 - 531
  • [36] Development of In Vitro-In vivo Correlation for Nimesulide Loaded Ethylcellulose Microparticles
    Khan, Shujaat A.
    Ahmad, Mahmood
    Murtaza, Ghulam
    Shoaib, Harris M.
    Aamir, Muhammad N.
    Kousar, Rozina
    Rasool, Fatima
    Madni, Asadullah
    LATIN AMERICAN JOURNAL OF PHARMACY, 2010, 29 (06): : 1029 - 1034
  • [37] In vitro-in vivo correlation of microsphere formulations: recent advances and challenges
    Kim, Sung Soo
    Ro, Si Won
    Na, Dong Hee
    JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 54 (01) : 37 - 49
  • [38] Combined Models for Data from In Vitro-In Vivo Correlation Experiments
    Jacobs, Tom
    Rossenu, Stefaan
    Dunne, Adrian
    Molenberghs, Geert
    Straetemans, Roel
    Bijnens, Luc
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (06) : 1197 - 1211
  • [39] Developing In Vitro-In Vivo Correlation of Risperidone Immediate Release Tablet
    Saibi, Yardi
    Sato, Hitoshi
    Tachiki, Hidehisa
    AAPS PHARMSCITECH, 2012, 13 (03): : 890 - 895
  • [40] Dissolution rate limited bioavailability of flutamide, and in vitro-in vivo correlation
    Posti, J
    Katila, K
    Kostiainen, T
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 49 (01) : 35 - 39